However, this strategy currently faces two challenges: firstly, some tumor cells exhibit very low proteasomal efficiency for mutp53, which hinders the presentation of p53-derived peptides; secondly, certain rapidly dividing normal cells express high levels of p53, which may lead to their recognition and attack by the immune system. This evidence concerns the gene TP53 and neoplasm.